Search
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. … It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
Categories: Compounds used in a research, industrial, or household settingDichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269ApprovedDichlorobenzyl alcohol is a mild antiseptic with a broad spectrum for bacterial and virus associated with mouth and throat infections. … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approvedChloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigationalEphedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]
Synonyms: L-Ephedrine, L(−)-ephedrineMixtures: COPHADYL-E COUGH LINCTUS, ColdaeWon Cold AGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical[A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in … [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: GINKGO AL 40 MG FTA, GINKGO AL 80 MG FTAMefloquine
go.drugbank.com/drugs/DB00358ApprovedMalaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIn clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. … [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA.